Intravenous versus intramuscular oxytocin injection for preventing uterine atonic primary postpartum haemorrhage in third stage of labour: A double-blind randomised controlled trial

To compare the efficacy and safety of intravenous and intramuscular oxytocin in preventing atonic primary postpartum haemorrhage in the third stage of labour. A double-blind randomised clinical study on consenting women without risk factors for primary postpartum haemorrhage in labour at term. Two h...

Full description

Saved in:

Bibliographic Details
Published in:	SAGE open medicine Vol. 12; p. 20503121241230484
Main Authors:	Okaforcha, Emmanuel Ikechukwu, Eleje, George Uchenna, Ikechebelu, Joseph Ifeanyichukwu, Ezeama, Chukwuemeka Okwudili, Igbodike, Emeka Philip, Ugwu, Emmanuel Onyebuchi, Okpala, Boniface Chukwuneme, Mbachu, Ikechukwu Innocent, Umeononihu, Osita Samuel, Ogabido, Chukwudi Anthony, Onwusulu, Daniel Nnaemeka, Oguejiofor, Charlotte Blanche, Okafor, Chidinma Charity, Olisa, Chinedu Lawrence, Ikwuka, David Chibuike, Ofor, Ifeanyichukwu Jude, Okafor, Chigozie Geoffrey
Format:	Journal Article
Language:	English
Published:	England SAGE Publications 01-01-2024 SAGE Publishing
Subjects:	Original intramuscular route oxytocin Intravenous route uterine atony third stage of labour primary postpartum haemorrhage
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	To compare the efficacy and safety of intravenous and intramuscular oxytocin in preventing atonic primary postpartum haemorrhage in the third stage of labour. A double-blind randomised clinical study on consenting women without risk factors for primary postpartum haemorrhage in labour at term. Two hundred and thirty-two women were randomly allotted into intravenous ( = 115) and intramuscular ( = 117) oxytocin groups in the active management of the third stage of labour. All participants received 10 IU of oxytocin, either IV or IM, and 1 ml of water for injection as a placebo via a route alternate to that of administration of oxytocin within 1 min of the baby's delivery. The primary outcome measures were mean postpartum blood loss and haematocrit change. Trial Registration No.: PACTR201902721929705. The baseline socio-demographic and clinical characteristics were similar between the two groups ( > 0.05). There was no statistically significant difference between the two groups with regards to the mean postpartum blood loss (254.17 ± 34.85 ml 249.4 ± 39.88 ml; = 0.210), haematocrit change (2.4 (0.8%) 2.1 (0.6%); = 0.412) or adverse effects ( > 0.05). However, the use of additional uterotonics was significantly higher in the intravenous group (25 (21.73%) 17 (14.53%); = 0.032). Although oxytocin in both study groups showed similar efficacy in terms of preventing atonic primary postpartum haemorrhage, participants who received intravenous oxytocin were more likely to require additional uterotonics to reduce their likelihood of having an atonic primary postpartum haemorrhage. However, both routes have similar side effect profiles.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	2050-3121 2050-3121
DOI:	10.1177/20503121241230484